Home
Science and IP
Investors
Our Team
Events
News Releases
Contact
NASDAQ: CMND
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
19
November
2026
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
Read More
16
November
2026
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
Read More
10
November
2026
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
Read More
27
Ocober
2026
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Trial
Read More
12
October
2026
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
Read More
8
October
2026
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Read More
7
October
2026
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
Read More
23
September
2026
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Read More
17
September
2026
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Read More
11
September
2026
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Read More
8
September
2026
Clearmind Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following...
Read More
4
September
2026
Clearmind Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Read More
1
September
2026
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Read More
24
August
2026
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support
Read More
13
August
2026
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Read More
Next